197 related articles for article (PubMed ID: 37663226)
1. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals.
McNamara B; Chang Y; Goreshnik A; Santin AD
Int J Womens Health; 2023; 15():1353-1365. PubMed ID: 37663226
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
[TBL] [Abstract][Full Text] [Related]
3. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
4. Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates in Gynecologic Cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract][Full Text] [Related]
6. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
7. Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
Nerone M; Grande MD; Sessa C; Colombo I
Explor Target Antitumor Ther; 2022; 3(2):149-171. PubMed ID: 36046840
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC; Powell SS; Pothuri B
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences.
Barreca M; Lang N; Tarantelli C; Spriano F; Barraja P; Bertoni F
Explor Target Antitumor Ther; 2022; 3(6):763-794. PubMed ID: 36654819
[TBL] [Abstract][Full Text] [Related]
10. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
11. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
12. Acquired Resistance to Antibody-Drug Conjugates.
Collins DM; Bossenmaier B; Kollmorgen G; Niederfellner G
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30897808
[TBL] [Abstract][Full Text] [Related]
13. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
Singh D; Dheer D; Samykutty A; Shankar R
J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates: beyond current approvals and potential future strategies.
Menon S; Parakh S; Scott AM; Gan HK
Explor Target Antitumor Ther; 2022; 3(2):252-277. PubMed ID: 36046842
[TBL] [Abstract][Full Text] [Related]
15. Recent Therapeutic Advances in Gynecologic Oncology: A Review.
Wilson EM; Eskander RN; Binder PS
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398161
[TBL] [Abstract][Full Text] [Related]
16. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
17. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
18. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
Zhang X; Huang AC; Chen F; Chen H; Li L; Kong N; Luo W; Fang J
Antib Ther; 2022 Jan; 5(1):18-29. PubMed ID: 35146330
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates: Ushering in a New Era of Cancer Therapy.
Hurwitz J; Haggstrom LR; Lim E
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631232
[TBL] [Abstract][Full Text] [Related]
20. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
Ma H; Sawas A
Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
